Cart
sales@molnova.com
GPRP
CAS No. 67869-62-9
GPRP( —— )
Catalog No. M34267 CAS No. 67869-62-9
GPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein IIb/IIIa complex (glycoprotein IIb/IIIa receptor).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGPRP
-
NoteResearch use only, not for human use.
-
Brief DescriptionGPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein IIb/IIIa complex (glycoprotein IIb/IIIa receptor).
-
DescriptionGPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number67869-62-9
-
Formula Weight425.48
-
Molecular FormulaC18H31N7O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : ≥ 50 mg/mL (117.51 mM)DMSO : 20.83 mg/mL (48.96 mM; Ultrasonic )
-
SMILESC([C@@H](NC(=O)[C@H]1N(C(CN)=O)CCC1)CCCNC(=N)N)(=O)N2[C@H](C(O)=O)CCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gallistl S, et al. Gly-pro-arg-pro (GPRP) enhances free thrombin. Thromb Res. 1995 Jun 15;78(6):547-50.?
molnova catalog
related products
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
Abrilumab
Abrilumab (MEDI-7183) is a fully human monoclonal antibody against α4β7 that inhibits the α4β7 integrin and can be used to study inflammatory bowel disease and ulcerative colitis.
-
RBC8
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
